ÂÜÀòÂÒÂ×

Laura Asinas Blackburn has a strong background in regulatory affairs and quality assurance, with experience in various pharmaceutical and biotechnology companies. Laura is currently serving as the Vice President and Head of Regulatory Affairs at Astria Therapeutics, Inc. since April 2022. Prior to this, they held the position of Executive Director of Regulatory Affairs and Quality Assurance at Morphic Therapeutic from January 2020 to April 2022. Laura also worked as a Senior Director of Regulatory Affairs and Quality Assurance at Morphic Therapeutic from May 2019 to January 2020. Before joining Morphic Therapeutic, Laura worked as an Independent Regulatory Consultant at Proteon Therapeutics from March 2011 to May 2019.

Earlier in their career, they served as a Regulatory Consultant at Verastem Oncology from 2016 to 2018. Laura also worked as an Independent Regulatory Affairs Consultant at Inotek Pharmaceuticals Corporation from November 2009 to August 2016. Laura has additional experience as an Independent Regulatory Affairs Consultant at NKT Therapeutics Inc. from February 2012 to February 2016, as a Regulatory Consultant at Sideris Pharmaceuticals from 2013 to 2015, as an Independent Regulatory Affairs Consultant at Infinity Pharmaceuticals from May 2012 to January 2014, as an Independent Regulatory Affairs Consultant at Foldrx Pharmaceuticals from November 2008 to May 2011, and as an Independent Regulatory Consultant at Elixir Pharmaceuticals from April 2009 to October 2009.

Laura Asinas Blackburn has a Juris Doctor (JD) degree in Law from the Western New England University School of Law. Laura also holds a Bachelor of Arts (BA) degree in Psychology from Wellesley College. However, the specific dates of their education at both institutions are unknown.